No abstract

Although this is a small cohort, disease-causing MEFV mutations and FMF disease rate were increased among our patients with IBD. The increase was prominent among CD patients, whereas in UC the rate was similar to the Turkish healthy control population.

According to our results from a Turkish pediatric population, lansoprazole is a suitable probe drug for phenotyping CYP2C19. The CYP2C19*2 and *17 variants should be taken into consideration in predicting the clinical outcome of therapy with lansoprazole in the pediatric population.

Amaç: Bu çal›flman›n amac› yeni tan› ve diet alt›ndaki çölyak hastalar› ile sa¤l›kl› çocuklardaki fekal kalprotektin miktar›n› karfl›laflt›rmakt›r. Ayr›ca histopatolojik evre (Marsh evresi) ve nötrofilik infiltrasyon derecesi ile de fekal kalprotektin oran› karfl›laflt› (s›ras›yla 117,2 μg/g (3.2-306), 3.7 μg/g (0.5-58.2) ve 9.6 μg/g (1-70), p<0.001). Gastrointestinal semptomu olan hastalarda di¤er gastrointestinal semptomu olmayan hastalara göre yüksek saptand› [142.8 (12.2-306) ve 79.7 (3.2-243.2 [142.8 (12.2-306) vs. 79.7 (3.2-243.2)

Mesalazine is a first-line drug in pediatric inflammatory bowel disease, and is effective as primary treatment and maintenance therapy. It's usually well tolerated, but various side effects have been described. A 15-year-old female with ulcerative colitis developed polyuria, polydipsia, vomiting, and fatigue. She was receiving mesalazine (500 mg, thrice daily, p.o.) and prednisolone for 4 months. She was detected as acute tubular injury as she had dehydration, acidosis, hypostenuria, hematuria, proteinuria, low levels of potassium, uric acid and bicarbonate. These findings were attributed to interstitial nephritis as a side effect of mesalazine, however as renal biopsy was disapproved by the parents, it was not confirmed. After discontinuation of mesalazine her renal tubular functions improved. Potassium and phosphorus supplements were stopped after 7 months, although she had to continue bicarbonate supplementation. We conclude that regular renal screening is important in patients receiving 5-ASA therapy to prevent rare but serious complications, such as interstitial nephritis sometimes leading to chronic renal failure.